Moderna Inc is poised to make regulatory filings in the US and Europe today for its Covid-19 vaccines. This follows the release of new data from a Phase 3 study showing that the messenger RNA (mRNA) vaccine achieved an efficacy rate of 94.1%. The placebo-controlled study involves 30,000 participants.
